MODERNA INC. DL-,0001 WKN: A2N9D9 ISIN: US60770K1079 Kürzel: MRNA Forum: Aktien Thema: Hauptdiskussion

Zulassung in der Schweiz nächste Woche am Dienstag oder Mittwoch erwartet schreibt cash.ch

https://theprint.in/health/vaccine-maker-iil-other-companies-in-touch-with-moderna-to-bring-its-covid-vaccine-to-india/582889/ 👌👌👌

https://www.bloomberg.com/opinion/articles/2021-01-09/pfizer-moderna-mrna-vaccines-could-vanquish-covid-today-cancer-tomorrow

😂

@keule. Unser Wette war Freitag. Und du hast verloren. Und wie du es verloren hast. Heul also nicht herum

Biontech wird kurzfristig bis zum letzten gap fallen 😜

Boar loony Don und ich haben ne wette auf biontech moderna geht Montag hoch, so bin besoffen gute Nacht kann nix mehr erklären heut siehe biontech forum,😂😂😂

Kann kein Englisch 😢

Looking back to our 2019-2020 objectives, we set out to generate human proof-of-concept data for multiple medicines, execute on our current development pipeline, create new development candidates in existing modalities and invent new modalities. We made tremendous progress against these objectives over the past two years and, at a time of unparalleled global disruption, we are emerging stronger than I could have imagined. I would like to thank and congratulate our relentless team of employees, many quite new to Moderna. They did all this and much more to advance our Mission for patients during a very complicated pandemic. Indeed, the SARS-CoV-2 virus changed everything. The positive Phase 3 analysis of our vaccine against COVID-19 has meaningful implications for all of our vaccines in development, all the vaccines in our research pipeline and all the vaccines that we are not yet working on in the labs. This is where the power of mRNA as an information molecule comes into play. We always said that it made no sense for Moderna to be a one-product company. We would be a zero-product company if we failed to get a product approved before running out of cash or we would have many dozens of products over time, changing medicine forever and impacting the lives of millions. Moderna is entering 2021 as a commercial company, with a strong cash position, clear strategic priorities and a team poised to continue advancing mRNA vaccines and therapeutics into new areas of high unmet need. I believe we have a very exciting journey ahead and we are pleased to have you with us. When I reflect on what the team has accomplished in the last 10 years since Moderna’s inception, going from a revolutionary but unproven concept to a commercial organization with more than 20 programs in development and the ability to generate cash to invest to rapidly scale our platform company, I wonder what Moderna will look like 10 years from now, in 2030.

Our mid-stage pipeline doubled in size, growing from two to four Phase 2 candidates, building on significant clinical data from 2019 that validated our mRNA platform. In support of our strategy to accelerate new development candidates in our core modalities, we introduced five development candidates in the first two months alone, adding to a rich, diversified pipeline of programs across infectious diseases, immuno-oncology, cardiovascular diseases, rare diseases, and autoimmune and inflammatory diseases. We saw a transformation in the number of patients and healthy volunteers enrolled in our studies from just above 2,000 a year ago to more than 32,000 today. Thanks to the hard work of many in support of our commitment to inclusion, our trial participants are representative of the communities at highest risk and of our diverse society. The early investment we made in our manufacturing and digital capabilities prepared us to rapidly scale our production to accommodate at least 500 million doses and potentially up to 1 billion doses of our COVID-19 vaccine in 2021. With this scale-up, our talented team grew significantly to support manufacturing, late-stage clinical development, regulatory and commercial readiness. As we expanded our geographic footprint, we built and deepened our relationships with partners across the globe including the National Institutes of Health (NIH), Lonza, Catalent, ROVI, Vertex and others. As we close our books for 2020, we expect that cash, cash equivalents and investments as of December 31, 2020 were approximately $5.25 billion. This means that our cash position has been approximately multiplied by four compared to 12 months ago, and we generated positive cash flows from operations in the third quarter for the first time in the company’s history.

Dear fellow shareholders, By nearly all measures, 2020 was a historic year in our lives. It was also a historic year for Moderna. We started the year not knowing there was going to be a new virus, which would be declared a global pandemic—the first of its kind in 100 years since the Spanish flu. We ended the year with an Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) and an Interim Order from Health Canada for use of our COVID-19 vaccine. Today, our team is working as hard as they can to manufacture with high quality as many doses of the vaccine as they can. We know that each additional dose we can make will be used to protect one more life. It took our team less than 12 months to go from the sequence made available online by the Chinese authorities to having completed a Phase 1, a Phase 2 and a 30,000 participant, placebo-controlled Phase 3 trial, and to get the vaccine authorized for use in the U.S. and Canada, with several other regulatory rolling reviews in process around the world. That is an extraordinary accomplishment for a biotech company of 1,300 people. Moderna is now a commercial company.

Achtung langer Text für Longs (catch that joke)

Ich verstehe aber nicht warum du denkst dass btnx am Montag fällt.... Der Flow sieht zu gut aus... Ist ein Traum

Mal sehen 😸

Wayne es interessiert, h2 afc energy, noch ist es ein penny stock, einfach mal mit beschäftigen, könnte nen tenbugger werden